vs

Side-by-side financial comparison of Cellebrite DI Ltd. (CLBT) and SelectQuote, Inc. (SLQT). Click either name above to swap in a different company.

SelectQuote, Inc. is the larger business by last-quarter revenue ($537.1M vs $292.2M, roughly 1.8× Cellebrite DI Ltd.). SelectQuote, Inc. runs the higher net margin — 12.9% vs -103.5%, a 116.4% gap on every dollar of revenue. Cellebrite DI Ltd. produced more free cash flow last quarter ($60.8M vs $-1.0M). Over the past eight quarters, Cellebrite DI Ltd.'s revenue compounded faster (72.8% CAGR vs 19.5%).

Cellebrite DI Ltd. is a digital forensics company headquartered in Petah Tikva, Israel that provides tools for law enforcement agencies as well as enterprise companies and service providers to collect, review, analyze and manage digital data. Their flagship product series is the Cellebrite UFED.

SelectQuote is a direct-to-consumer distribution platform for selling insurance policies and healthcare services. Their insurance business earns commissions by connecting consumers with insurance carriers that provide senior health, life, automobile, and home insurance. The healthcare services business mainly consists of SelectRx, an accredited pharmacy. The company went public on May 21, 2020.

CLBT vs SLQT — Head-to-Head

Bigger by revenue
SLQT
SLQT
1.8× larger
SLQT
$537.1M
$292.2M
CLBT
Higher net margin
SLQT
SLQT
116.4% more per $
SLQT
12.9%
-103.5%
CLBT
More free cash flow
CLBT
CLBT
$61.9M more FCF
CLBT
$60.8M
$-1.0M
SLQT
Faster 2-yr revenue CAGR
CLBT
CLBT
Annualised
CLBT
72.8%
19.5%
SLQT

Income Statement — Q3 FY2025 vs Q2 FY2026

Metric
CLBT
CLBT
SLQT
SLQT
Revenue
$292.2M
$537.1M
Net Profit
$-302.3M
$69.3M
Gross Margin
84.6%
61.8%
Operating Margin
14.1%
14.0%
Net Margin
-103.5%
12.9%
Revenue YoY
11.6%
Net Profit YoY
30.2%
EPS (diluted)
$-1.50
$0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLBT
CLBT
SLQT
SLQT
Q4 25
$537.1M
Q3 25
$292.2M
$328.8M
Q2 25
$220.8M
$345.1M
Q1 25
$89.6M
$408.2M
Q4 24
$481.1M
Q3 24
$232.1M
$292.3M
Q2 24
$185.3M
$307.2M
Q1 24
$71.2M
$376.4M
Net Profit
CLBT
CLBT
SLQT
SLQT
Q4 25
$69.3M
Q3 25
$-302.3M
$-30.5M
Q2 25
$36.9M
$12.9M
Q1 25
$-71.4M
$26.0M
Q4 24
$53.2M
Q3 24
$-44.5M
Q2 24
$-95.2M
$-31.0M
Q1 24
$-40.6M
$8.6M
Gross Margin
CLBT
CLBT
SLQT
SLQT
Q4 25
61.8%
Q3 25
84.6%
41.4%
Q2 25
84.1%
47.2%
Q1 25
85.2%
60.2%
Q4 24
67.5%
Q3 24
83.5%
55.7%
Q2 24
84.1%
60.7%
Q1 24
82.6%
71.8%
Operating Margin
CLBT
CLBT
SLQT
SLQT
Q4 25
14.0%
Q3 25
14.1%
-12.4%
Q2 25
12.1%
-3.6%
Q1 25
10.3%
5.4%
Q4 24
14.7%
Q3 24
7.9%
-4.1%
Q2 24
11.7%
-0.5%
Q1 24
0.2%
8.8%
Net Margin
CLBT
CLBT
SLQT
SLQT
Q4 25
12.9%
Q3 25
-103.5%
-9.3%
Q2 25
16.7%
3.7%
Q1 25
-79.7%
6.4%
Q4 24
11.1%
Q3 24
-15.2%
Q2 24
-51.4%
-10.1%
Q1 24
-57.0%
2.3%
EPS (diluted)
CLBT
CLBT
SLQT
SLQT
Q4 25
$0.26
Q3 25
$-1.50
$-0.26
Q2 25
$0.15
$-0.06
Q1 25
$-0.36
$0.03
Q4 24
$0.30
Q3 24
$-0.35
$-0.26
Q2 24
$-0.48
$-0.17
Q1 24
$-0.21
$0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLBT
CLBT
SLQT
SLQT
Cash + ST InvestmentsLiquidity on hand
$191.7M
$18.3M
Total DebtLower is stronger
$405.8M
Stockholders' EquityBook value
$336.0M
$359.7M
Total Assets
$690.6M
$1.4B
Debt / EquityLower = less leverage
1.13×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLBT
CLBT
SLQT
SLQT
Q4 25
$18.3M
Q3 25
$191.7M
$10.7M
Q2 25
$326.1M
$32.4M
Q1 25
$191.7M
$80.1M
Q4 24
$7.3M
Q3 24
$189.5M
$10.4M
Q2 24
$178.6M
$42.7M
Q1 24
$189.5M
$37.8M
Total Debt
CLBT
CLBT
SLQT
SLQT
Q4 25
$405.8M
Q3 25
$393.1M
Q2 25
$385.1M
Q1 25
$391.5M
Q4 24
$711.9M
Q3 24
$680.4M
Q2 24
$683.3M
Q1 24
$686.0M
Stockholders' Equity
CLBT
CLBT
SLQT
SLQT
Q4 25
$359.7M
Q3 25
$336.0M
$305.1M
Q2 25
$408.4M
$351.1M
Q1 25
$336.0M
$350.2M
Q4 24
$326.0M
Q3 24
$34.2M
$269.4M
Q2 24
$-40.2M
$316.8M
Q1 24
$34.2M
$346.8M
Total Assets
CLBT
CLBT
SLQT
SLQT
Q4 25
$1.4B
Q3 25
$690.6M
$1.2B
Q2 25
$787.4M
$1.2B
Q1 25
$690.6M
$1.3B
Q4 24
$1.3B
Q3 24
$532.9M
$1.1B
Q2 24
$556.6M
$1.2B
Q1 24
$532.9M
$1.2B
Debt / Equity
CLBT
CLBT
SLQT
SLQT
Q4 25
1.13×
Q3 25
1.29×
Q2 25
1.10×
Q1 25
1.12×
Q4 24
2.18×
Q3 24
2.53×
Q2 24
2.16×
Q1 24
1.98×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLBT
CLBT
SLQT
SLQT
Operating Cash FlowLast quarter
$66.2M
$52.0K
Free Cash FlowOCF − Capex
$60.8M
$-1.0M
FCF MarginFCF / Revenue
20.8%
-0.2%
Capex IntensityCapex / Revenue
1.8%
0.2%
Cash ConversionOCF / Net Profit
0.00×
TTM Free Cash FlowTrailing 4 quarters
$172.1M
$8.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLBT
CLBT
SLQT
SLQT
Q4 25
$52.0K
Q3 25
$66.2M
$-21.6M
Q2 25
$53.5M
$-37.5M
Q1 25
$10.0M
$71.1M
Q4 24
$-28.7M
Q3 24
$58.2M
$-16.6M
Q2 24
$24.6M
$20.0M
Q1 24
$12.5M
$44.5M
Free Cash Flow
CLBT
CLBT
SLQT
SLQT
Q4 25
$-1.0M
Q3 25
$60.8M
$-22.7M
Q2 25
$47.5M
$-38.0M
Q1 25
$8.5M
$70.2M
Q4 24
$-29.0M
Q3 24
$55.3M
$-17.1M
Q2 24
$21.0M
$19.7M
Q1 24
$11.4M
$43.4M
FCF Margin
CLBT
CLBT
SLQT
SLQT
Q4 25
-0.2%
Q3 25
20.8%
-6.9%
Q2 25
21.5%
-11.0%
Q1 25
9.5%
17.2%
Q4 24
-6.0%
Q3 24
23.8%
-5.8%
Q2 24
11.3%
6.4%
Q1 24
16.0%
11.5%
Capex Intensity
CLBT
CLBT
SLQT
SLQT
Q4 25
0.2%
Q3 25
1.8%
0.3%
Q2 25
2.7%
0.1%
Q1 25
1.7%
0.2%
Q4 24
0.1%
Q3 24
1.3%
0.2%
Q2 24
1.9%
0.1%
Q1 24
1.5%
0.3%
Cash Conversion
CLBT
CLBT
SLQT
SLQT
Q4 25
0.00×
Q3 25
Q2 25
1.45×
-2.91×
Q1 25
2.73×
Q4 24
-0.54×
Q3 24
Q2 24
Q1 24
5.20×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLBT
CLBT

Subscription services$197.2M67%
Term-license$60.8M21%
Professional services$23.2M8%
Other non-recurring$11.0M4%

SLQT
SLQT

Healthcare Services Segment$230.7M43%
Pharmacy$227.2M42%
Other$30.4M6%
Final Expense$20.4M4%
Term$18.5M3%
Other Senior$6.3M1%
All Other Revenue$3.9M1%

Related Comparisons